Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials

[1] Wong J(2013)Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 1033-1046

[2] Constantino M(2015)Morbidity and mortality in young-onset type 2 diabetes in comparison to type 1 diabetes: where are we now? Curr Diab Rep 15 566-511

[3] Yue DK(2016)Cost effectiveness of type 2 diabetes screening: a systematic review Med J Islamic Repub Iran 30 326-718

[4] Najafi B(2001)Projection of diabetes burden through 2050 Diabetes Care 24 1936-570

[5] Farzadfar F(2016)Predictions burden of diabetes and economics cost: contributing risk factors of changing disease prevalence and its pandemic impact to Qatar Exp Clin Endocrinol Diabetes 124 504-314

[6] Ghaderi H(1993)Ethnic differences in risk factors associated with the prevalence of non-insulin-dependent diabetes mellitus. The San Luis Valley diabetes study Am J Epidemiol 137 706-658

[7] Hadian M(2003)The emerging science of body weight regulation and its impact on obesity treatment J Clin Invest 111 565-549

[8] Boyle JP(2015)Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence Value Health 18 308-1469

[9] Honeycutt AA(2016)Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies BMJ Open 6 e012527-37

[10] Narayan KM(2010)Pharmacokinetics of dipeptidylpeptidase-4 inhibitors Diabetes Obes Metab 12 648-1946

[1] Wong J(2013)Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 1033-1046

[2] Constantino M(2015)Morbidity and mortality in young-onset type 2 diabetes in comparison to type 1 diabetes: where are we now? Curr Diab Rep 15 566-511

[3] Yue DK(2016)Cost effectiveness of type 2 diabetes screening: a systematic review Med J Islamic Repub Iran 30 326-718

[4] Najafi B(2001)Projection of diabetes burden through 2050 Diabetes Care 24 1936-570

[5] Farzadfar F(2016)Predictions burden of diabetes and economics cost: contributing risk factors of changing disease prevalence and its pandemic impact to Qatar Exp Clin Endocrinol Diabetes 124 504-314

[6] Ghaderi H(1993)Ethnic differences in risk factors associated with the prevalence of non-insulin-dependent diabetes mellitus. The San Luis Valley diabetes study Am J Epidemiol 137 706-658

[7] Hadian M(2003)The emerging science of body weight regulation and its impact on obesity treatment J Clin Invest 111 565-549

[8] Boyle JP(2015)Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence Value Health 18 308-1469

[9] Honeycutt AA(2016)Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies BMJ Open 6 e012527-37

[10] Narayan KM(2010)Pharmacokinetics of dipeptidylpeptidase-4 inhibitors Diabetes Obes Metab 12 648-1946